The Hidden Burden and Real World Impact of TD
Describe the physical, psychological, and socioeconomic impact of TD symptoms and recognize how under-identification can delay meaningful care.
When “mild” does not mean low burden
Many patients experience meaningful social, occupational, and emotional harm even when abnormal movements appear limited during a visit.
TD can affect a substantial share of patients exposed to antipsychotic therapy, yet many remain undiagnosed in routine care.
Visible severity and day-to-day burden do not always line up. Social avoidance, stigma, and medication nonadherence may still be high.
Respiratory and swallowing-related manifestations can be clinically important and may be mistaken for primary cardiopulmonary disease.
The impact extends beyond the patient and may include missed work, emotional strain, and greater caregiving responsibilities.
Test whether the learner can identify respiratory dyskinesia versus a primary cardiopulmonary explanation.
Bridging the Gap with Standardized Assessment Tools
Use a more complete assessment framework that captures movement severity and functional burden rather than relying on observation alone.
Severity plus impact
A more useful workflow pairs a structured movement tool with targeted questions or tools focused on social, psychological, physical, and vocational burden.
Best for movement observation and severity.
Helpful when burden is high, but visible movement may seem limited during the visit.
Routine monitoring often falls short of best-practice recommendations.
What do you do when the patient says the burden is severe, but the room exam looks subtle?
This is where impact-oriented assessment matters. Visible movement alone can miss the real-world burden.
Choose the best assessment approach for a high-functioning patient with stigma and functional decline despite subtle movements.
Evidence Based Treatment and VMAT 2 Inhibitor Titration
Differentiate first-line TD treatments from outdated practices and apply a more patient-specific titration mindset.
Anticholinergics are not a solution for TD and may delay effective management.
VMAT 2 inhibitors are the key evidence-based treatment class for TD.
Titration should reflect response, tolerability, potential interactions, and metabolism-related considerations.
Non-normal CYP2D6 status can materially affect exposure and may justify more careful dose limits and planning.
Select treatment logic that reflects current evidence
Treat TD directly while preserving needed psychiatric therapy when appropriate. Then tailor titration to the patient, not just the label.
Apply a treatment and titration plan to a patient with metabolism-related considerations.
Module Complete
You now have a stronger, cleaner Real World CE training experience with functional checkpoints, progress tracking, and a polished finish screen.